Recombinant multi-species IL-19/IL19 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis
Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine IL-19/IL19 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
The protein encoded by this gene is a cytokine that belongs to the IL10 cytokine subfamily. This cytokine is found to be preferentially expressed in monocytes. It can bind the IL20 receptor complex and lead to the activation of the signal transducer and activator of transcription 3 (STAT3). A similar cytokine in mouse is reported to up-regulate the expression of IL6 and TNF-alpha and induce apoptosis, which suggests a role of this cytokine in inflammatory responses. Alternatively spliced transcript variants encoding the distinct isoforms have been described. [provided by RefSeq, Jul 2008]
The Alternative Names of target: IL-10C,IL-19,IL19,Il19,Interleukin-19,MDA1,Melanoma differentiation-associated protein-like protein,NG.1,ZMDA1
Go
to IL-19/IL19 products collection
>>
(antibodies,
antigen, VLP, mRNA, ORF viral vector, etc)
Product information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-T44584-Ag-1/ GM-Tg-hg-T44584-Ag-2 | Human IL-19/IL19 protein | Human |
| GM-Tg-rg-T44584-Ag-1/ GM-Tg-rg-T44584-Ag-2 | Rat IL-19/IL19 protein | Rat |
| GM-Tg-mg-T44584-Ag-1/ GM-Tg-mg-T44584-Ag-2 | Mouse IL-19/IL19 protein | Mouse |
| GM-Tg-cynog-T44584-Ag-1/ GM-Tg-cynog-T44584-Ag-2 | Cynomolgus/Rhesus macaque IL-19/IL19 protein | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-T44584-Ag-1/ GM-Tg-felg-T44584-Ag-2 | Feline IL-19/IL19 protein | Feline |
| GM-Tg-cang-T44584-Ag-1/ GM-Tg-cang-T44584-Ag-2 | Canine IL-19/IL19 protein | Canine |
| GM-Tg-bovg-T44584-Ag-1/ GM-Tg-bovg-T44584-Ag-2 | Bovine IL-19/IL19 protein | Bovine |
| GM-Tg-equg-T44584-Ag-1/ GM-Tg-equg-T44584-Ag-2 | Equine IL-19/IL19 protein | Equine |
Size: 1mg | 10mg | 100mg
Product Description
| Catalog No. |
GM-Tg-hg-T44584-Ag-1/ GM-Tg-hg-T44584-Ag-2;
GM-Tg-rg-T44584-Ag-1/ GM-Tg-rg-T44584-Ag-2;
GM-Tg-mg-T44584-Ag-1/ GM-Tg-mg-T44584-Ag-2; GM-Tg-cynog-T44584-Ag-1/ GM-Tg-cynog-T44584-Ag-2; GM-Tg-felg-T44584-Ag-1/ GM-Tg-felg-T44584-Ag-2; GM-Tg-cang-T44584-Ag-1/ GM-Tg-cang-T44584-Ag-2; GM-Tg-bovg-T44584-Ag-1/ GM-Tg-bovg-T44584-Ag-2; GM-Tg-equg-T44584-Ag-1/ GM-Tg-equg-T44584-Ag-2 |
| Products Name | IL-19/IL19 protein |
| Species | Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine |
| Target Name | IL-19/IL19 |
| Protein Sub-location | Secreted Protein/Potential Cytokines |
| Isotypes | Recombinant protein |
| Expression platform | Mammalian cell |
| Bioactivity validation | Affintiy&bioactivity validated by ELISA, cell culture validated. |
| Tag | His |
| Products description | Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine IL-19/IL19 protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation & Reconstitution |
Lyophilized from GM's Protein Stability Buffer2
(PSB2,Confidential Ingredients) or PBS
(pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
About Gmab

GMab, developed by GeneMedi, constitutes an
advanced library of recombinant
monoclonal antibodies, each meticulously
designed to target specific molecular
entities. Leveraging the sophisticated
capabilities of GM’s Taurus™ and LIBRA™
platforms, GMab synthesizes antibodies
characterized by high binding affinity,
exceptional physicochemical stability, and
optimal developability profiles.
Through
expression in mammalian cell lines, GMab has
been established as a paradigmatic
reference antibody. It holds significance in
myriad domains of biological drug
discovery, encompassing cellular cultivation,
innovative assay methodologies,
strategic animal model systematization, in-depth
pharmacokinetic & pharmacodynamic
(PK/PD) modeling, and intricate mechanism of
action (MOA) investigations.